Skip to main content
SpringerLink
Log in

Thrombin Activable Fibrinolysis Inhibitor in Beta Thalassemia

  • Original Article
  • Published:
The Indian Journal of Pediatrics Aims and scope Submit manuscript

Abstract

Objectives

To study plasma levels of Thrombin activable fibrinolysis inhibitor (TAFI) in children with β-thalassemia major.

Methods

Fifty β-thalassemia major patients, 1.4 to 17 y of age, with number of transfusions received varying from 21 to 162 were selected at random and complete blood count (CBC), coagulation parameters [Prothrombin time (PT), Activated partial thromboplastin time (aPTT), fibrinogen, D-dimer, protein C, protein S, antithrombin, Tissue plasminogen activator (t-PA), Plasminogen activator inhibitor (PAI-1)] and TAFI were performed.

Results

PT and aPTT were prolonged in 18 % and 30 % of cases respectively. Reduced activity of Protein C (PC) was observed in 50 % of cases and Protein S (PS) was reduced in 54 % of cases. t-PA levels were significantly higher in cases. TAFI levels were 17.24 ± 4.05 ng/ml which were significantly higher than the control group (15.01 ± 3.28; p = 0.003) No significant correlation of TAFI was observed with Hb, platelet counts, liver enzymes, serum ferritin, PC, PS, D-dimer, t-PA or PAI-1.

Conclusions

There is an ongoing subclinical activation of coagulation cascade and fibrinolytic system in thalassemia major (TM) patients. Higher levels of TAFI in the present study with no significant correlation with other parameters were noted, thus pointing out to its independent role in contribution to hypercoagulable state in thalassemia. TAFI serves as a link between two limbs of hemostasis, with its higher levels promoting inhibition of fibrinolytic system and thus promoting a hypercoagulable state. Performing TAFI levels in thalassemic patients could help to detect the early coagulopathy in these patients and hence these patients can be closely monitored for any evidence of thrombosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Taher A. Iama’eel H, Cappellini MD. Thalassemia intermedia: revisited. Blood Cells Mol Dis. 2006;37:12–20.

    Article  CAS  PubMed  Google Scholar 

  2. Winichagoon P, Fucharoen S, Wasi P. Increased circulating platelet aggregates in thalassemia. Southeast Asian J Trop Med Public Health. 1981;12:556–60.

    CAS  PubMed  Google Scholar 

  3. Cappellini MD. Coagulation in the pathophysiology of hemolytic anemias. Hematology Am Soc Hematol Educ Program. 2007;1:74–8.

    Google Scholar 

  4. Eldor A, Rachmilewitz EA. The hypercoagulable state in thalassemia. Blood. 2002;99:36–43.

    Article  CAS  PubMed  Google Scholar 

  5. Butthep P, Bunyaratvej A, Funahara Y, et al. Possible evidence of endothelial cell activation and disturbance in thalassemia: an in vitro study. Southeast Asian J Trop Med Public Health. 1997;28:141–8A.

    PubMed  Google Scholar 

  6. Hovav T, Goldfarb A, Artmann G, Yedgar S, Barshtein G. Enhanced adherence of beta thalassemic erythrocytes to endothelial cells. Br J Haematol. 1999;106:178–81.

    Article  CAS  PubMed  Google Scholar 

  7. Naithani R, Chandra J, Narayan S, Sharma S, Singh V. Thalassemia major- on verge of bleeding or thrombosis? Haematology. 2006;11:57–61.

    Article  CAS  Google Scholar 

  8. Mokhtar GM, Matter RM, Shawki H, Abdel Aziz MM. Thrombin activable fibrinolysis inhibitor (TAFI): relationship to haemostatic alteration in patients with beta thalassemia. Pediatr Hematol Oncol. 2010;27:363–73.

    Article  CAS  PubMed  Google Scholar 

  9. Nesheim M, Bajzar L. The discovery of TAFI. J Thromb Haemost. 2005;3:2139–46.

    Article  CAS  PubMed  Google Scholar 

  10. Mosneir LO, Bouma BN. Regulation of fibrinolysis by thrombin activable fibrinolysis inhibitor, an unstable carboxypeptidase B that unites the pathway of coagulation and fibrinolysis. Arterioscler Thromb Vasc Biol. 2006;26:2445–53.

    Article  Google Scholar 

  11. Boffa MB, Koschinsky ML. Curiouser and curiouser: recent advances in measurements of thrombin activable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation and biological roles. Clin Biochem. 2007;40:431–42.

    Article  CAS  PubMed  Google Scholar 

  12. Bertina RM, Tilburg LH, Haverkate F, et al. Discovery of thrombin activable fibrinolysis inhibitor (TAFI). J Thromb Haemost. 2006;4:256–7.

    Article  CAS  PubMed  Google Scholar 

  13. Mosnier LO, Buijtenhuijs P, Marx PF, Meijers JCM, Bouma BN. Identification of thrombin activable fibrinolysis inhibitor (TAFI) in human platelets. Blood. 2003;10:4844–6.

    Article  Google Scholar 

  14. Schadinger SL, Linn JHH, Garand M, Boffa MB. Secretion and antifibrinolytic function of thrombin- activable fibrinolysis inhibitor from human platelets. J Thromb Haemost. 2010;8:2523–9.

    Article  CAS  PubMed  Google Scholar 

  15. Zhao L, Morser J, Bajzar L, Nesheim M, Naqashima M. Identification and characterization of two thrombin activable fibrinolysis inhibitor isoforms. Thromb Hemost. 1998;80:949–55.

    CAS  Google Scholar 

  16. Bajzar L, Morser J, Neshim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem. 1996;271:16603–8.

    Article  CAS  PubMed  Google Scholar 

  17. Marx PF, Hackeng TM, Dawson PE, Griffin JH, Meijers JCM, Bouma BN. Inactivation of thrombin activable fibrinolysis inhibitor takes place by process that involves conformational instability rather than proteolytic cleavage. J Biol Chem. 2000;275:12410–5.

    Article  CAS  PubMed  Google Scholar 

  18. Boffa MB, Wang W, Bajzar L, Nesheim ME. Plasma and recombinant thrombin activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin dependent activation, thermal stability and enzymatic properties. J Biol Chem. 1998;273:2127–35.

    Article  CAS  PubMed  Google Scholar 

  19. Boffa MB, Bell R, Stevens WK, Nesheim ME. Roles of thermal instability and proteolytic cleavage in regulation of activated thrombin activable fibrinolysis inhibitor. J Biol Chem. 2000;275:12868–78.

    Article  CAS  PubMed  Google Scholar 

  20. Mosnier LO, von den Borne PA, Meijers JC, Bouma BN. Plasma TAFI levels influences the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost. 1998;80:829–35.

    CAS  PubMed  Google Scholar 

  21. Biswas A, Tiwari AK, Ranjan R, et al. Thrombin activable fibrinolysis inhibitor gene polymorphisms are associated with antigenic levels in the Asian-Indian population but may not be a risk for stroke. Br J Hematol. 2008;143:581–8.

    CAS  Google Scholar 

  22. Tilburg N, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and risk of deep vein thrombosis. Blood. 2000;95:2855–9.

    PubMed  Google Scholar 

  23. Eser M, Kement M, Balin S. Is there any role of thrombin activable fibrinolysis inhibitor in the development of a hypercoagulable state in gastric cancer? World J Surg Oncol 2012;10:180.

  24. Caocci L, Alberti M, Burrai P, Corda R. Screening coagulation tests and clotting factors in homozygous β- thalassemia. Acta Haematol. 1978;60:358–64.

    Article  CAS  PubMed  Google Scholar 

  25. Musumeci S, Leonardi S, Dio R, Fischer A, Costa G, Protein C. And antithrombin III in polytransfused thalassemic patients. Acta Haematol. 1987;77:30–3.

    Article  CAS  PubMed  Google Scholar 

  26. Angchaisuksiri P, Atichartakarn V, Aryurachai K, et al. Hemostatic and thrombotic markers in patients with hemoglobin E/ beta- thalassemia disease. Am J Hematol. 2007;82:1001–4.

    Article  CAS  PubMed  Google Scholar 

  27. Tripatara A, Jetsrisuparb A, Teeratakulpisarn J, Kuaha K. Haemostatic alterations in splenectomized and non-splenectomized patients with β-thalassemia/ hemoglobin E disease. Thromb Res. 2007;120:805–10.

    Article  CAS  PubMed  Google Scholar 

  28. Shirahata A, Funahara Y, Opartkiattikul N, Fucharoen S, Laosombat V, Yamada K. Protein C and protein S deficiency in thalassemic patients. Southeast Asian J Trop Med Public Health. 1992;23:65–73.

    PubMed  Google Scholar 

  29. Teli A, Economou M, Tzovaras F, et al. Subclinical central nervous system involvement and thrombophilic status in young thalassemia intermedia patients of Greek origin. Blood Coag. Fibrinolysis. 2012;23:195–202.

    Article  Google Scholar 

  30. Kemhali S, Gurman C, Egin Y, et al. Hypercoagulability in children with thalassemia major. Clin Appl Thromb Haemostat. 1997;3:129–32.

    Article  Google Scholar 

Download references

Contributions

AC: Preparation of manuscript, critical analysis and statistics analysis; SS and AN: Overall supervision of the study; JC: Provided with clinical details. SS will act as guarantor for the paper.

Author information

Authors and Affiliations

  1. Department of Pathology, Lady Hardinge Medical College, New Delhi, India

    Aruna Chhikara, Sunita Sharma & Anita Nangia

  2. Department of Pediatrics, Lady Hardinge Medical College, New Delhi, India

    Jagdish Chandra

Authors
  1. Aruna Chhikara
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sunita Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jagdish Chandra
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anita Nangia
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aruna Chhikara.

Ethics declarations

Conflict of Interest

None.

Source of Funding

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chhikara, A., Sharma, S., Chandra, J. et al. Thrombin Activable Fibrinolysis Inhibitor in Beta Thalassemia. Indian J Pediatr 84, 25–30 (2017). https://doi.org/10.1007/s12098-016-2208-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12098-016-2208-x

Keywords

Search

Navigation